Reported 10 months ago
Anchor BioTech (7754) will be listed on the emerging stock market on the 25th of this month, focusing on developing First-in-Class and Best-in-Class small molecule new drugs for skin, nerve, and rare diseases. Major shareholders include Taiwan Cement, Fubon Financial, with the top ten shareholders holding 58.1% of shares. The company’s core products target diseases like Kennedy's disease/spinal muscular atrophy, chemotherapy-induced peripheral neuropathy, and male baldness, aiming to address unmet medical needs in these areas.
Source: YAHOO